Selexipag for Chronic Thromboembolic Pulmonary Hypertension in Japanese Patients　― A Double-Blind, Randomized, Placebo-Controlled, Multicenter Phase II Study ―-Reference-Cited by-同舟云学术

Selexipag for Chronic Thromboembolic Pulmonary Hypertension in Japanese Patients　― A Double-Blind, Randomized, Placebo-Controlled, Multicenter Phase II Study ―

Published:2020-09-25 Issue:10 Volume:84 Page:1866-1874
ISSN:1346-9843
Container-title:Circulation Journal
language:en
Short-container-title:Circ J

Author:

Tanabe Nobuhiro¹,Fukuda Keiichi²,Matsubara Hiromi³,Nakanishi Norifumi⁴,Tahara Nobuhiro⁵,Ikeda Satoshi⁶,Kishi Takuya⁷,Satoh Toru⁸,Hirata Ken-ichi⁹,Inoue Teruo¹⁰,Kimura Hiroshi¹¹,Okano Yoshiaki¹²,Okazaki Osamu¹³,Sata Masataka¹⁴,Tsujino Ichizo¹⁵,Ueno Shuichi¹⁶¹⁷,Yamada Norikazu¹⁸,Yao Atsushi¹⁹,Kuriyama Takayuki²⁰

Affiliation:

1. Department of Respirology, Graduate School of Medicine, Chiba University

2. Department of Cardiology, Keio University School of Medicine

3. Director of Entire Medical Departments, National Hospital Organization Okayama Medical Center

4. Department of Cardiology, Osaka Namba Clinic

5. Department of Medicine, Division of Cardiovascular Medicine, Kurume University School of Medicine

6. Department of Cardiovascular Medicine, Nagasaki University Graduate School of Biomedical Sciences

7. Department of Cardiology, Graduate School of Medical Sciences, International University of Health and Welfare

8. Department of Cardiovascular Medicine, Kyorin University Hospital

9. Cardiovascular Medicine, Kobe University Graduate School of Medicine

10. Department of Cardiovascular Medicine, Dokkyo Medical University School of Medicine

11. Respiratory Disease Center, Fukujuji Hospital

12. Department of Intermal Medicine, Hanwa Dai-ni Senboku Hospital

13. Department of Cardiology, National Center for Global Health and Medecine

14. Department of Cardiovascular Medicine, Tokushima University Graduate School of Biomedical Sciences

15. The First Department of Medicine, Hokkaido University School of Medicine

16. Department of Internal Medicine Division of Cardiovascular Medicine, Jichi Medical University School of Medicine

17. Ueno Clinic

18. Department of Cardiology, Kuwana City Medical Center

19. Department of Cardiovascular Medicine, The University of Tokyo Hospital

20. Kuriyama Clinic

Publisher

Japanese Circulation Society

Subject

Cardiology and Cardiovascular Medicine,General Medicine

Link

https://www.jstage.jst.go.jp/article/circj/84/10/84_CJ-20-0438/_pdf

Reference30 articles.

1. 1. Becattini C, Agnelli G, Pesavento R, Silingardi M, Poggio R, Taliani MR, et al. Incidence of chronic thromboembolic pulmonary hypertension after a first episode of pulmonary embolism. Chest 2006; 130: 172–175.

2. 2. Fedullo PF, Auger WR, Kerr KM, Rubin LJ. Chronic thromboembolic pulmonary hypertension. N Engl J Med 2001; 345: 1465–1472.

3. 3. Hoeper MM, Mayer E, Simonneau G, Rubin LJ. Chronic thromboembolic pulmonary hypertension. Circulation 2006; 113: 2011–2020.

4. 4. Galiè N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, et al. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2015; 46: 903–975.

5. 5. Pepke-Zaba J, Ghofrani HA, Hoeper MM. Medical management of chronic thromboembolic pulmonary hypertension. Eur Respir Rev 2017; 26: 160107.

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparing the efficacy and safety of low, medium, and high dosages of selexipag for treating pulmonary hypertension: A systematic review and meta‐analysis;Animal Models and Experimental Medicine;2023-09-23

2. Impact of residual pulmonary hypertension on long‐term outcomes after pulmonary endarterectomy in the modern era;Pulmonary Circulation;2023-04

3. Selexipag in Patients With Pulmonary Hypertension: A Systematic Review and Meta-Analysis of Randomized Controlled Trials;Current Problems in Cardiology;2023-02

4. Efficacy and safety of non-prostanoid prostacyclin receptor agonist for pulmonary hypertension: A meta-analysis;Pulmonary Pharmacology & Therapeutics;2023-02

5. Efficacy and safety of selexipag, an oral prostacyclin receptor agonist for the treatment of pulmonary hypertension: A meta-analysis;Pulmonary Pharmacology & Therapeutics;2022-02